Cholesterol-Modified Anti-Il6 siRNA Reduces the Severity of Acute Lung Injury in Mice
Cells · 30.04.2024 · 13 (9) · 767
DOI: 10.3390/cells13090767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 30.04.2024. Verfasst von Ivan V Chernikov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Acad. Lavrentiev Ave. 8, 630090 Novosibir…. Hauptthemen laut MEDLINE: Acute Lung Injury, Cholesterol, Interleukin-6, RNA, Small Interfering. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, project ICBFM SB RAS.
Abstract (Originalsprache)
Small interfering RNA (siRNA) holds significant therapeutic potential by silencing target genes through RNA interference. Current clinical applications of siRNA have been primarily limited to liver diseases, while achievements in delivery methods are expanding their applications to various organs, including the lungs. Cholesterol-conjugated siRNA emerges as a promising delivery approach due to its low toxicity and high efficiency. This study focuses on developing a cholesterol-conjugated anti-Il6 siRNA and the evaluation of its potency for the potential treatment of inflammatory diseases using the example of acute lung injury (ALI). The biological activities of different Il6-targeted siRNAs containing chemical modifications were evaluated in J774 cells in vitro. The lead cholesterol-conjugated anti-Il6 siRNA after intranasal instillation demonstrated dose-dependent therapeutic effects in a mouse model of ALI induced by lipopolysaccharide (LPS). The treatment significantly reduced Il6 mRNA levels, inflammatory cell infiltration, and the severity of lung inflammation. IL6 silencing by cholesterol-conjugated siRNA proves to be a promising strategy for treating inflammatory diseases, with potential applications beyond the lungs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Acad. Lavrentiev Ave. 8, 630090 Novosibirsk, Russia.
- Faculty of Natural Sciences, Novosibirsk State University, Pirogova Str., 1, 630090 Novosibirsk, Russia.
ORCID-Profile: Aleksandra V Sen'kova, Mariya I Meschaninova, Innokenty A Savin, Marina A Zenkova, Elena L Chernolovskaya
Förderung
- Russian Science Foundation
- project ICBFM SB RAS
Zitieren
APA
Chernikov, I. V., Bachkova, I. K., Sen'kova, A. V., Meschaninova, M. I., Savin, I. A., Vlassov, V. V., Zenkova, M. A., & Chernolovskaya, E. L. (2024). Cholesterol-Modified Anti-Il6 siRNA Reduces the Severity of Acute Lung Injury in Mice. Cells, 13(9), 767. https://doi.org/10.3390/cells13090767
Vancouver
Chernikov IV, Bachkova IK, Sen'kova AV, Meschaninova MI, Savin IA, Vlassov VV, et al. Cholesterol-Modified Anti-Il6 siRNA Reduces the Severity of Acute Lung Injury in Mice. Cells. 2024;13(9):767. doi:10.3390/cells13090767
BibTeX
@article{Chernikov2024,
author = {Chernikov, Ivan V and Bachkova, Irina K and Sen'kova, Aleksandra V and Meschaninova, Mariya I and Savin, Innokenty A and Vlassov, Valentin V and Zenkova, Marina A and Chernolovskaya, Elena L},
title = {Cholesterol-Modified Anti-Il6 siRNA Reduces the Severity of Acute Lung Injury in Mice},
journal = {Cells},
year = {2024},
volume = {13},
number = {9},
pages = {767},
doi = {10.3390/cells13090767}
}
EUVIMED